PCM
OBIO icon

Pinz Capital Management’s Orchestra BioMed OBIO Stock Holding History

Pinz Capital Management’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-6,400
Closed -$65K – 191
2021
Q4 		$65K Buy
+6,400
New +$63.1K 0.03% 282

Other funds holding OBIO

DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AC
Amitell Capital Singapore $62.4M AUM 75.98% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Pinz Capital Management's OBIO Position: Q1 2022 in Review

Pinz Capital Management sold out of Orchestra BioMed (OBIO) in Q1 2022, closing a stake of 6,400 shares — an estimated $65K sold.

Pinz Capital Management first reported a position in OBIO in Q4 2021 and held it in 1 quarter. The position peaked at $65K in Q4 2021. 59 funds tracked by Wall St. Rank hold OBIO as of Q1 2022.

  • Pinz Capital Management reported no remaining Orchestra BioMed position as of Q1 2022 after selling out during the quarter.
  • Pinz Capital Management sold 6,400 Orchestra BioMed shares in Q1 2022, an estimated $65K.
  • Pinz Capital Management first reported a position in Orchestra BioMed in Q4 2021 and held it in 1 quarter.
  • Pinz Capital Management's Orchestra BioMed position peaked at $65K in Q4 2021.
  • 59 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2022.

Based on Pinz Capital Management's 13F filing for Q1 2022, filed 16 May 2022.